Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759614 | 0.84 | CYP4F2 (0.53) | PKMMAPTNPSR1NPC1POLB | |
| SCHEMBL2684136 | 0.83 | KMT2A (0.41) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL6626640 | 0.80 | SMN1; SMN2 (0.45) | PKMKMT2AMEN1TDP1MAPT | |
| SCHEMBL28190418 | 0.80 | PKM (0.43) | PKMKMT2AMEN1TDP1MAPT | |
| SCHEMBL2779430 | 0.79 | PKM (0.46) | PKMKMT2AMEN1TDP1TSHR | |
| SCHEMBL28565287 | 0.78 | KMT2A (0.48) | PKMKMT2AMEN1TDP1MAPT | |
| SCHEMBL7960171 | 0.77 | NPSR1 (0.46) | PKMKMT2AMEN1MAPTNPSR1 | |
| SCHEMBL28511312 | 0.76 | SLC6A4 (0.41) | KMT2ANPC1POLBRAB9ATP53 | |
| SCHEMBL6626017 | 0.75 | MAPK1 (0.42) | PKMKMT2AMEN1TDP1MAPT | |
| SCHEMBL3052561 | 0.75 | MAPK1 (0.58) | PKMKMT2ATDP1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724127-B | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| CN-114829357-A | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| CN-112724127-A | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2021-04-30 | — | — | CN | disclosed |
| US-20180134726-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| EP-2854541-A1 | PLANT GROWTH REGULATING COMPOUNDS | Syngenta Participations AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174846-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174846-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| US-8404728-B2 | Small-molecule botulinum toxin inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120114696-A1 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | US ARMY, SECRETARY OF THE ARMY | 2012-05-10 | — | — | US | disclosed |
| US-7321012-B2 | Method of crosslinking intrinsically conductive polymers or intrinsically conductive polymer precursors and the articles obtained therefrom | THE UNIVERSITY OF CONNECTICUT (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2005014693-A1 | METHOD OF CROSSLINKING INTRINSICALLY CONDUCTIVE POLYMERS OR INTRINSICALLY CONDUCTIVE POLYMER PRECURSORS AND THE ARTICLES OBTAINED THEREFROM | UNIVERSITY OF CONNECTICUT (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040242792-A1 | Method of crosslinking intrinsically conductive polymers or intrinsically conductive polymer precursors and the articles obtained therefrom | CONNECTICUT, THE UNIVERSITY OF | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134726-A1 | PLANT GROWTH REGULATING COMPOUNDS | GHITM, GHDC, AREG | PKM 2331/4885KMT2A 3559/4885MEN1 4061/4885 |
| US-20120114696-A1 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | BTD, BCHE, ACHE | PKM 4012/4885KMT2A 1949/4885MEN1 2693/4885 |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | PKM 3897/4885KMT2A 4730/4885MEN1 1799/4885 |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, TPMT | PKM 811/4885KMT2A 4602/4885MEN1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.